F2G LTD

1. F2G LTD 1999-07-29 → present
2. FUNCTIONAL FUNGAL GENOMICS LTD 1998-06-10 → 1999-07-29

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

UK-adopted International Accounting Standards

Reporting scope

Consolidated group

Auditor

PricewaterhouseCoopers LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“As of 31 December 2024, the Group had cash of £73,281,330 (2023: £50,457,366). The Group has incurred recurring losses, for the year ended 31 December 2024 the Group incurred a loss of £32,902,955 (2023: £43,676,507). In addition, the Group had accumulated losses of £204,908,634 as of 31 December 2024 (2023: £172,097,668). The net cash flow used by operating and investing activities was £25,433,017 for the year ended 31 December 2024 (2023: £50,244,556): The Group expects to continue to incur significant expenses and operating losses for the foreseeable future. The Group assessed its ability to continue as a going concern and determined that it expeots that its cash and cash oquivalents ac of 31 December 2023, will be sufficient to enable the Group and Company to fund its operating expenses, debt service obligations and capital expenditure requirements into at least the fourth quarter of 2026.”

Group structure

1. F2G LTD · parent
   1. F2G Biotech GmbH 100% · Austria · Research and development on biotechnology
   2. F2G Inc 100% · USA · Research and development on biotechnology

Significant events

• “In May 2022 F2G and Shionogi & Co., Ltd entered a strategic collaboration to develop and commercialize olorofim for invasive fungal infections in Europe and Asia. The agreement included an upfront payment of $100m to F2G.”
• “In June 2023, F2G has received a Complete Response Letter ("CRL") from the U.S. Food and Drug Administration ("FDA") for olorofim for the treatment of invasive fungal infections in patients who have limited or no treatment options following a submission of an NDA based on a subset of its Phase 2 b open label clinical trial data.”
• “In July 2024, F2G closed an $80 million equity financing round with new and existing investors and in August 2024, the company extended the equity financing round by an additional $20 million.”
• “In March 2025, F2G extended the $100 million equity financing round closed in 2024 by an additional $7.5 million with a new investor.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

7

last 12 months

Capital events

6

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  —

  Not reported

• Cash

  +45.2%

  £50,457,366 → £73,281,330

• Net assets

  +46.4%

  -£12,945,102 → -£6,933,345

• Employees

  -26.4%

  72 → 53

• Operating profit

  +33.3%

  -£41,246,077 → -£27,508,545

• Profit before tax

  +26.8%

  -£46,681,903 → -£34,181,720

• Wages

  -27.4%

  £15,306,341 → £11,119,538

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers